WCLC 2025 - Posters & ePosters-P1.17.59 Real-World Uptake of Immunotherapy for Stage III-IV Non-Small Cell Lung Cancer: Insights From the National Cancer Database (2016-2021)

P1.17.59 Real-World Uptake of Immunotherapy for Stage III-IV Non-Small Cell Lung Cancer: Insights From the National Cancer Database (2016-2021)

Back to course

Pdf Summary

This retrospective study analyzed real-world adoption and disparities in immune checkpoint inhibitor (ICI) therapy among 130,328 patients diagnosed with Stage III-IV non-small cell lung cancer (NSCLC) between 2016 and 2021, using data from the National Cancer Database. The primary outcome was the receipt of immunotherapy, with trends assessed annually and multivariable logistic regression employed to evaluate associations between ICI use and socioeconomic, demographic, and facility-level factors.<br /><br />Findings revealed a substantial increase in ICI utilization, rising from 10% in 2016 to 41% by 2021, with the most significant growth observed between 2016 and 2019, likely reflecting the influence of pivotal clinical trials endorsing ICIs. Despite this positive trend, fewer than half of eligible patients received recommended ICIs, indicating underuse relative to clinical expectations.<br /><br />The study identified disparities in ICI receipt linked to demographic and socioeconomic factors. Patients treated at academic institutions had higher odds of receiving ICIs compared to non-academic centers. Racial and ethnic disparities were noted, with Black patients less likely than White patients to receive ICI therapy, while Asian/Pacific Islander patients had higher odds. Insurance status also influenced treatment, with privately insured patients more likely than those on Medicaid to receive ICIs. Other variables such as higher median household income and urban location correlated with increased ICI use.<br /><br />These findings underscore ongoing gaps in equitable access to immunotherapy for advanced NSCLC, highlighting the need for targeted interventions to address disparities across socioeconomic and demographic groups. Future research should focus on identifying barriers to ICI uptake and developing strategies to ensure broader, more uniform adoption of immunotherapy, thereby improving outcomes in lung cancer care on a population level.

Asset Subtitle

Brittany Morguelan

Meta Tag

Speaker Brittany Morguelan

Topic Global Health, Health Services, and Health Economics

Keywords

immune checkpoint inhibitors

non-small cell lung cancer

NSCLC

immunotherapy adoption

health disparities

socioeconomic factors

racial disparities

insurance status

academic vs non-academic centers

lung cancer treatment trends